[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].

Jun Shi, Yufang Wang, Jing Zheng, Jianya ZhouPubMed 2025 · DOI

TL;DR

This review paper provides a comprehensive overview of the latest advancements in diagnosing and treating KRASG12C-mutant non-small cell lung cancer (NSCLC). It highlights the evolution of diagnostic techniques, the emergence of targeted therapies, and the promising strategies for overcoming drug resistance, offering a valuable resource for clinicians and researchers in the field.

What Problem Does This Paper Address?

Lung cancer remains a leading cause of cancer-related deaths globally, with non-small cell lung cancer (NSCLC) being the most common type. A significant subset of NSCLC patients harbor mutations in the Kirsten rat sarcoma viral oncogene (KRAS), with the KRASG12C mutation being a prevalent subtype. Historically, KRAS mutations were considered "undruggable" due to the protein's structure, leaving a substantial patient population with limited targeted treatment options. This paper addresses the critical need for updated information on effective diagnostic methods and therapeutic strategies for this specific patient group, aiming to improve patient outcomes.

Methods

The paper reviews a wide range of diagnostic techniques for KRAS mutations, primarily focusing on two main platforms: Polymerase Chain Reaction (PCR) and sequencing. It details various derivative technologies within these platforms, including:

  • PCR-based methods: Allele-specific PCR (AS-PCR), Amplification Refractory Mutation System-PCR (ARMS-PCR), Droplet Digital PCR (ddPCR), Chip Digital PCR (cdPCR), and BEAMing technology. These methods are evaluated for their sensitivity, specificity, throughput, and applicability in both tissue and liquid biopsies.
  • Sequencing-based methods: Sanger sequencing and Next-Generation Sequencing (NGS) are discussed, along with pyrosequencing and CRISPR/Cas system-based diagnostic approaches.

For therapeutic advancements, the paper synthesizes data from clinical trials and real-world studies on approved and investigational KRASG12C targeted drugs. It also explores combination therapeutic strategies, including combinations with chemotherapy, immune checkpoint inhibitors (ICIs), SHP2 inhibitors, and EGFR monoclonal antibodies.

Datasets

Not explicitly detailed as a dataset in the traditional machine learning sense. The paper synthesizes information from numerous clinical trials, retrospective studies, and real-world data analyses involving patients with KRASG12C-mutant NSCLC. These studies form the basis for evaluating diagnostic accuracy and therapeutic efficacy.

Key Insights and Ideas

  • The "undruggable" KRAS is now druggable: The discovery of a specific binding pocket (switch II pocket, S-IIP) in KRASG12C has enabled the development of targeted covalent inhibitors, transforming treatment paradigms.
  • Diagnostic technologies are rapidly evolving: From traditional PCR to advanced digital PCR and NGS, the ability to detect KRAS mutations with high sensitivity and specificity, even in liquid biopsies, has significantly improved. This allows for more precise patient stratification and monitoring.
  • Resistance is a major hurdle, but combination therapies offer hope: While single-agent targeted therapies show efficacy, acquired resistance is common. Combining KRASG12C inhibitors with chemotherapy, ICIs, SHP2 inhibitors, or EGFR inhibitors are emerging as promising strategies to overcome resistance and enhance patient outcomes.
  • Biomarkers are crucial for personalized treatment: Co-mutations like STK11 and KEAP1 are consistently associated with poorer survival, highlighting the need for personalized treatment strategies and combination approaches for these patient subgroups.
  • Liquid biopsy is a game-changer: The increasing utility of liquid biopsies for KRAS mutation detection offers a less invasive and dynamic way to monitor treatment response and detect resistance mechanisms.

Key Results

  • Diagnostic advancements: Technologies like ddPCR and BEAMing can detect mutations at extremely low frequencies (0.03%-0.05%), crucial for early detection and monitoring. NGS is the guideline-recommended tool for comprehensive mutation profiling.
  • Approved KRASG12C inhibitors: Drugs like Sotorasib, Adagrasib, Fulzerasib, Garsorasib, and Glecirasib have shown objective response rates (ORRs) ranging from 26% to 51% in clinical trials and real-world studies, with median progression-free survival (mPFS) generally under a year.
  • Combination therapy efficacy: Early results from combination strategies show promising ORRs, for example, Sotorasib with chemotherapy achieving an ORR of 88.9%, and Sotorasib with ICIs showing ORRs around 29-74% depending on the specific ICI and patient population.
  • Brain metastasis control: Adagrasib, with its enhanced blood-brain barrier penetration, has shown activity in brain metastases.

Limitations and Future Work

  • Limited first-line data: Most clinical studies focus on heavily pre-treated patients, with a lack of high-level evidence for first-line targeted therapy or combination strategies. Larger trials are needed to establish optimal first-line treatment.
  • Real-world vs. trial data: Real-world data for Sotorasib often shows lower efficacy than in clinical trials, suggesting that strict patient selection in trials may not fully represent the general patient population. More real-world studies are needed for all approved KRASG12C inhibitors.
  • Lack of head-to-head comparisons: There is a significant need for direct comparative studies between different KRASG12C inhibitors to guide clinical decision-making, especially in specific scenarios like brain metastases or post-progression.
  • Addressing co-mutations: The negative prognostic impact of co-mutations like STK11 and KEAP1 is well-established, but prospective studies investigating targeted interventions for these specific patient groups are lacking.
  • Future directions: The authors emphasize the need for high-level clinical research on first-line treatments and personalized combination strategies, robust real-world and head-to-head comparative studies, and further exploration of biomarker-driven precision medicine. Investigating specific combination regimens for patients with STK11/KEAP1 co-mutations and strengthening research into resistance mechanisms and novel drug development are also highlighted.

Summary updated

Abstract

Lung cancer stands as the primary cause of cancer-related mortalities globally, presenting a severe menace to human health. In individuals with non-small cell lung cancer (NSCLC), Kirsten rat sarcoma viral oncogene (KRAS) mutations serve as crucial oncogenic drivers. NSCLC with KRASG12C mutation is among the most prevalent subtypes. Currently, the detection methods for KRAS mutations predominantly concentrate on polymerase chain reaction (PCR) and sequencing platforms. The diverse derivative technologies of these two platforms each exhibit distinct merits and demerits in terms of testing performance and detection throughput, and find significant applications in tissue biopsy and liquid biopsy. In targeted therapies, KRASG12C targeted drugs, including Sotorasib, Adagrasib, Fulzerasib, Garsorasib, and Glecirasib, have demonstrated certain therapeutic efficacies in clinical trials and have obtained marketing approval. To tackle drug resistance and enhance patient's prognoses, combination therapeutic strategies that integrate targeted agents with chemotherapy, immune checkpoint inhibitors, Src homology region 2 domain-containing phosphatase 2 (SHP2) inhibitors, and epidermal growth factor receptor (EGFR) monoclonal antibodies have emerged. This paper systematically reviews the advancements in the diagnosis and targeted therapy of NSCLC with KRASG12C mutation, aiming to offer a reference for the selection of clinical treatment regimens and subsequent research. .
BibTeX
@inproceedings{shi2025advances,
  author = {Jun Shi and Yufang Wang and Jing Zheng and Jianya Zhou},
  title = {{[Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant Non-small Cell Lung Cancer].}},
  booktitle = {PubMed},
  year = {2025},
  doi = {10.3779/j.issn.1009-3419.2025.101.13},
}
Figure